{
    "nctId": "NCT06359054",
    "briefTitle": "The Role of 68GA DOTATATE PET/CT In Breast Cancer Imaging",
    "officialTitle": "The Role of 68GA DOTATATE PET/CT In Breast Cancer Imaging; a Prospective Study Compared With 18F FDG PET/CT",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NA",
    "primaryPurpose": "DIAGNOSTIC",
    "enrollmentCount": 16,
    "primaryOutcomeMeasure": "Comparative Diagnostic Accuracy of 68Ga DOTATATE and 18F FDG PET/CT",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Age: 18 to 90 years old\n* Performance status: Karnofsky score 70 or better or WHO performance status 2 or better\n* Pathologically proven breast cancer by biopsy\n* Patients must be able to understand the meaning of the study and sign the appropriate Ethical Committee approved informed consent documents in the presence of the designated staff\n\nExclusion Criteria:\n\n* Any medical or psychiatric condition that compromises the subject\u00b4s ability to participate in the study\n* Any other significant disease including liver or renal disease\n* Pregnant or lactating women",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}